Navigation Links
Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Date:4/27/2009

- Updated Data from Initial Cohort Shows Nine of 14 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response -

- Patient Dosing Underway in Expansion Stage of Trial with Target of Enrolling 46 Patients Overall -

TUSTIN, Calif., April 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that updated preliminary data from its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer showed that nine of 14 evaluable patients in the initial cohort achieved an objective tumor response after a maximum of six treatment cycles according to RECIST criteria. The company also reported that patient dosing is underway in the expansion stage of the trial, which will enroll an additional 31 patients for a total of 46 advanced breast cancer patients overall.

"We are pleased to see these additional objective tumor responses in these advanced breast cancer patients who received up to six treatment cycles of bavituximab and chemotherapy," said Steven W. King, president and CEO of Peregrine. "These updated results further strengthen the positive data we reported in February after two treatment cycles, which had already exceeded the pre-defined number of objective tumor responses needed to expand the trial to the larger cohort."

Mr. King added, "While preliminary, these data along with early positive data from our other two bavituximab Phase II cancer trials are increasing our optimism that bavituximab in combination with chemotherapy could prove to be a valuable new option for the treatment of a variety of solid cancers. We look forward to reporting data from this expanded trial in the coming months."

The primary objective of the multi-center
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
2. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
3. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
4. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
5. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
6. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
7. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
8. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
11. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 Natera, Inc., a leader ... published in Ultrasound in Obstetrics & Gynecology ... non-invasive prenatal test (NIPT) can identify a complete ... A study based upon data collected in ... in about 1 in 1,000 pregnancies, although other ...
(Date:5/28/2015)... 2015 BioNorth Texas (BioNorthTX), an ... the life sciences industry in northern region of ... at The Foundry in Dallas on April 27, ... together a broad spectrum of biotech professionals from ... early successes in partnering with key life sciences ...
(Date:5/28/2015)... RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... therapeutics, primarily in the areas of dermatology and ophthalmology, ... 26 million units at a price to the public ... $10.4 million. Each unit consists of (i) one share ... to purchase 0.50 of a share of common stock ...
(Date:5/28/2015)... , May 28, 2015  GenVec, Inc. (Nasdaq: ... Douglas J. Swirsky , will present a company ... 11 a.m. EDT on Thursday, June 4, 2015. ... Swirsky,s presentation will be available at the following link:  ... on GenVec,s website.  To access, visit www.genvec.com , ...
Breaking Biology Technology:First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3GenVec To Present At The Jefferies Healthcare Conference 2
... & ... Compliance, ... health conditions that require intra-vaginal drug delivery and,the abundance of intravaginal ... of women find their current treatment,options "unacceptable" or "intolerable". The survey, ...
... Underway, MONTVALE, N.J., May 13 Synvista Therapeutics,Inc. ... in a 160-patient Phase 2 study,of alagebrium in patients ... the A.G.E. [Advanced Glycation End Product],Breaker Alagebrium in Diastolic ... assess the effect of six months,of oral treatment with ...
... Palatin Technologies,Inc. (Amex: PTN ) today reported ... 31, 2008 and announced new strategic objectives as ... and development,programs. Palatin will continue to develop products ... obesity, and,cardiovascular fields, including acute hospital care products ...
Cached Biology Technology:72% of Women Are Dissatisfied With Their Current Treatment of Vaginal Infection, Survey Finds 2Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 2Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 3Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 4Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 2Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 3Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 4Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 6Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 7
(Date:5/22/2015)... May 22, 2015 According to ... Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), ... and Utilities, Consumer and Home) - Global Forecast to ... from $2.77 Billion in 2015 to $6.19 Billion by ... Browse 79 market data Tables and   43 Figures ...
(Date:5/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... 3D-ID LLC, a company engaged in biometric identification is ... technology portion of the recently awarded TIES (Technical Information ... the Army. 3D-ID LLC has a suite ... enforcement and security agencies. Gino Pereira ...
(Date:5/18/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... in preventing some of the stresses of open surgery on ... and organ dysfunction. Laparoscopy is a type of surgery in ... By adding another gas to the carbon dioxide used ... University Medical Center have found they can preserve more normal ...
... that are associated with the health of the human ... scientists from 63 centres in Europe and Australia sheds ... The new findings provide hope for better treatment ... and asthma. In the past it has been difficult ...
... FORT COLLINS, COWild Malus orientalis species of wild ... applesare native to the Middle East and Central Asia. ... M. orientalis varieties from Georgia and Armenia ... narrows the large population and establishes a core collection ...
Cached Biology News:Gas improves blood flow and organ status during minimally invasive surgery 2New genes for lung disease discovered 2Understanding apples' ancestors 2
... • Holds 0.1 mL - 25 mL pipets ... Also accommodates most standard square or round pipet cans. ... four compartments, each 76 mm W x 76 mm ... 11 3/8 ins.). Overall dimensions: 89 mm W x ...
...
CoverWell imaging chamber gasket with adhesive, one chamber, 20 mm diameter, 1.0 mm deep *set of 40* Cell Biology Imaging Tools and Accessories Microscope Slide Accessories...
...
Biology Products: